Would you use a PSMA test obtained as part of a clinical trial to alter your treatment management?

If PSMA is being obtained as part of a clinical trial protocol, the protocol would specify how the information would be used. PSMA should be thought of as just a more sensitive PET Axumin scan. When PSMA is approved by the FDA (and gets paid for), it will likely replace PET Axumin in staging for patients with biochemical failure post-prostatectomy. At some point, it should replace current staging studies (BS and CT) in appropriately risk groups. One important thing that we will see (as Dr. Berlin noted at ASTRO), expect a “Will Rogers” phenomenon.